FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

[cafead]

via RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema
Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept

article source